References
- Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 5(8), e172 (2008).
- The Agree Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual. Saf. Health Care 12(1), 18–23 (2003).
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 7(3), e1000251 (2010).
- Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 88(9), 965–968 (1999).
- Lindell-Osuagwu L, Korhonen MJ, Saano S, Helin-Tanninen M, Naaranlahti T, Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J. Clin. Pharm. Ther. 34(3), 277–287 (2009).
- Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin. Drug Saf. 5(5), 703–718 (2006).
- Burns LE, Hodgman JE, Cass AB. Fatal circulatory collapse in premature infants receiving chloramphenicol. N. Engl. J. Med. 261, 1318–1321 (1959).
- Andersen DH, Blanc WA, Crozier DN, Silverman WA. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 18(4), 614–625 (1956).
- Fost N. Ethical dilemmas in medical innovation and research: distinguishing experimentation from practice. Semin. Perinatol. 22(3), 223–232 (1998).
- Olski TM, Lampus SF, Gherarducci G, Saint Raymond A. Three years of paediatric regulation in the European Union. Eur. J. Clin. Pharmacol. 67(3), 245–252 (2011).
- Hoppu K, Anabwani G, Garcia-Bournissen F et al. The status of paediatric medicines initiatives around the world – what has happened and what has not? Eur. J. Clin. Pharmacol. 68(1), 1–10 (2012).
- O’Leary M, Krailo M, Anderson JR, Reaman GH; Children’s Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin. Oncol. 35(5), 484–493 (2008).
- Fanaroff AA, Hack M, Walsh MC. The NICHD neonatal research network: changes in practice and outcomes during the first 15 years. Semin. Perinatol. 27(4), 281–287 (2003).
- Berezny K, Smith P, Benjamin DK Jr. Future of the NICHD Pediatric Trial Network. e-J. Neonatol. Res/ 1(2), 109–111 (2011).
- Shaddy RE, Denne SC; Committee on Drugs and Committee on Pediatric Research. Clinical report – guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 125(4), 850–860 (2010).
- Ruperto N, Eichler I, Herold R et al. A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). Arch. Dis. Child. 97(3), 185–188 (2012).
- Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? A view from regulators. PLoS Med. 9(4), e1001202 (2012).
- Ross JS, Lehman R, Gross CP. The importance of clinical trial data sharing: toward more open science. Circ. Cardiovasc. Qual. Outcomes 5(2), 238–240 (2012).
- Krumholz HM. Open science and data sharing in clinical research: basing informed decisions on the totality of the evidence. Circ. Cardiovasc. Qual. Outcomes 5(2), 141–142 (2012).
- Krekels EH, DeJongh J, van Lingen RA et al. Predictive performance of a recently developed population pharmacokinetic model for morphine and its metabolites in new datasets of (preterm) neonates, infants and children. Clin. Pharmacokinet. 50(1), 51–63 (2011).
Websites
- Frakking FNJ, van der Lee JH, Klassen M, Offringa M; For the StaR-Child Health Group. Survey of current guidance for child health clinical trials. www.who.int/childmedicines/publications/GUIDANCECHILDHEALTH.pdf (Accessed 22 June 2012)
- Pediatrics. Open access supplement on Child Health Research Standards. http://pediatrics.aappublications.org/content/129/Supplement_3.toc (Accessed 21 June 2012)
- US FDA. Pediatric-Labeling Changes table. www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM163159.pdf (Accessed 28 April 2012)
- InPharm. EMA grants first paediatric use marketing authorisation. www.inpharm.com/news/166770/ema-puma-viropharma-buccolam (Accessed 28 April 2012)
- American Academy of Pediatrics. US/Canadian Pediatric Clinical Research Network Directory. www2.aap.org/pros/capri/results.cfm (Accessed 28 April 2012)
- Children’s Oncology Group. www.childrensoncologygroup.org/index.php/about (Accessed 28 April 2012)
- Neonatal Research Network. Active and completed studies. https://neonatal.rti.org/studies.cfm (Accessed 28 April 2012)
- Internation Conference on Harmonisation. Clinical investigation of medicinal products in the pediatric population. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step4/E11_Guideline.pdf (Accessed 28 June 2012)
- US FDA. Guidance for industry – general considerations for pediatric pharmacokinetic studies for drugs and biological products. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf (Accessed 02 July 2012)
- ERA-NET PrioMedChild. www.priomedchild.eu/home/ (Accessed 28 April 2012)
- Global Research in Pediatrics Network. www.grip-network.org/ (Accessed 28 April 2012)
- US FDA. FDA pharmacometrics 2020 strategic goals. www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm167032.htm#FDAPharmacometrics2020StrategicGoals (Accessed 28 April 2012)